Clinical trial
Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric…
NCT00447330 · Duke University, Other · Completed
Key facts
| NCT number | NCT00447330 |
|---|---|
| Title | Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma |
| Official title | A Phase ll Study of Oxaliplatin, Capecitabine, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas |
| Acronym | XAGastric |
| Lead sponsor | Duke University, Other |
| Collaborators | Hoffmann-La Roche Industry Sanofi Genentech, Inc. |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Esophageal Neoplasms, Stomach Neoplasms, Neoplasm Metastasis |
| Intervention type | Drug |
| Interventions | capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin) |
| Enrollment | 60 |
| Start date | Feb 1, 2007 |
| Primary completion | Jan 1, 2014 |
| Completion | Jul 1, 2014 |
| First posted | Mar 14, 2007 |
| Last update posted | Feb 13, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- 1–9 Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: